Global Next-Generation Antibody Therapeutics Market: Market Segments: By Therapeutic Area (Oncology Autoimmune/Inflammatory); By Technology (Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered Antibodies, Antibody Fragments and Antibody-like Proteins & Biosimilar Antibody Products);and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030

$5,000$10,000

Global next-generation antibody therapeutics market to surpass USD 14.26 million by 2030 from USD 4.69 million in 2019 at a CAGR of 13.69% throughout the forecast period, i.e. 2019-30.

Clear

Description

Global Next-Generation Antibody Therapeutics Market: Market Segments: By Therapeutic Area (Oncology Autoimmune/Inflammatory); By Technology (Antibody-Drug Conjugates (ADCs), Bispecific Antibodies, Fc-engineered Antibodies, Antibody Fragments and Antibody-like Proteins & Biosimilar Antibody Products); and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030

Product Overview

Use of a new improvised therapeutic antibody to form novel medicines for the treatment of different diseases includes next-generation antibody therapeutics. Next-generation antibody therapeutics have been clinically developed for many diseases by pharmaceutical and biotechnology firms. Next-generation antibody-based therapeutics for the treatment of different medical conditions such as cancer, infectious diseases, and autoimmune diseases improve the current properties of therapeutic antibodies.

Market Highlights

Global next-generation antibody therapeutics market to surpass USD 14.26 million by 2030 from USD 4.69 million in 2019 at a CAGR of 13.69% throughout the forecast period, i.e. 2019-30.
The worldwide increase in the occurrence of different chronic diseases, the increase in the use of therapeutic antibodies, the production and invention of new medicines, and the increase in research and development activities for the preparation of new therapies are the key factors that are fueling the worldwide rise in the demand for next-generation antibody therapeutics.

Global Next-Generation Antibody Therapeutics Market: Segments
Oncology Segment to grow with the highest CAGR of XX.X% during 2019-30
Global Next-Generation Antibody Therapeutics Market is segmented by therapeutic area into oncology and autoimmune/inflammatory. The greater market share in 2019 was accounted for by the oncology segment and is expected to see the highest growth during the forecast period due to the rising incidence of cancer globally. The key factors for market growth are the growing prevalence of cancer worldwide, where next-generation antibodies serve as the predominant therapy and new product launches.
Global Next-Generation Antibody Therapeutics Market: Market Dynamics

Drivers

Increasing investments in healthcare infrastructural development
During the forecast period, the global next-generation demand for antibody therapeutics is likely to expand at a significant rate. This is largely due to the success of antibody therapeutics for chronic conditions such as cancer and autoimmune diseases of the next generation. Generally speaking, antibody therapeutics have experienced clear scientific developments to improve their effectiveness.

Restraint

High cost involved in research and development for developing next-generation antibodies
Different governments have implemented numerous stringent rules and regulations relating to the use of antibodies, which are significantly hampering the global demand for next-generation antibody therapeutics.
Global Next-Generation Antibody Therapeutics Market: Regions
Global next-generation antibody therapeutics market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, APAC, and MENA. Global next-generation antibody therapeutics market in North America held the largest market share of XX.X% in the year 2019 and due to growing R&D activities, technical advancements in antibody therapies, growing healthcare expenditure, and increasing government initiatives in this area, growth over the forecast period is expected to be sustained. Also, the growth of the market is driven by the growing prevalence of chronic diseases and by the growing approval of new medicines. It is anticipated that the growing occurrence of multiple diseases, growing advances in therapeutic antibodies, evolving antibody technologies, rising demand for better healthcare services, and rapid growth in biosimilar antibodies and engineered antibodies will bring new opportunities for the region’s next-generation therapeutic antibody industry.
Global Next-Generation Antibody Therapeutics Market: Key Players
 Bristol-Myers Squibb
o Company Overview
o Business Strategy
o Key Product Offerings
o Financial Performance
o Key Performance Indicators
o Risk Analysis
o Recent Development
o Regional Presence
o SWOT Analysis
 Pfizer
 Roche
 Bristol-Myers Squibb
 Amgen
 AstraZeneca
 Bayer
 Takeda Pharmaceuticals
 Biogen
 Seattle Genetics
 ImmunoGen
 Kyowa Hakko Kirin
 Xencor
 Dyax Corp
Global Next-Generation Antibody Therapeutics Market report also contains analysis on:
Global next-generation antibody therapeutics market Segments:
 By Therapeutic Area:
o Oncology
o Autoimmune/Inflammatory
 By Technology:
o Antibody-Drug Conjugates (ADCs)
o Bispecific Antibodies
o Fc-engineered Antibodies
o Antibody Fragments and Antibody-like Proteins
o Biosimilar Antibody Products
 Next-generation antibody therapeutics Market Dynamics
 Next-generation antibody therapeutics Market Size
 Supply & Demand
 Current Trends/Issues/Challenges
 Competition & Companies Involved in the Market
 Value Chain of the Market
 Market Drivers and Restraints

Additional information

Publisher

Geography Covered

Date Published

,

Pages

Format

Table of Contents

Contents
1. Executive Summary
2. Global Next-Generation Antibody Therapeutics Market
1. Product Overview
2. Market Definition
3. Segmentation
4. Assumptions and Acronyms
3. Research Methodology
1. Research Objectives
2. Primary Research
3. Secondary Research
4. Forecast Model
5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
1. Growth Drivers
2. Restraints
3. Opportunity
4. Trends
7. Correlation & Regression Analysis
1. Correlation Matrix
2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
1. Demand Risk Analysis
2. Supply Risk Analysis
10. Global Next-Generation Antibody Therapeutics Market Analysis
1. Porters Five Forces
1. Threat of New Entrants
2. Bargaining Power of Suppliers
3. Threat of Substitutes
4. Rivalry
2. PEST Analysis
1. Political
2. Economic
3. Social
4. Technological
11. Global Next-Generation Antibody Therapeutics Market
1. Market Size & forecast, 2019A-2030F
1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12. Global Next-Generation Antibody Therapeutics Market: Market Segmentation
1. By Regions
1. North America: (U.S. and Canada) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3. By Technology: Market Share (2020-2030F)
12.3.1. Antibody-Drug Conjugates (ADCs), By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.2. Bispecific Antibodies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.3. Antibody Fragments and Antibody-like Proteins, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.4. Fc-engineered Antibodies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.5. Biosimilar Antibody Products, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
1. Company Profile
1. Hoffmann-La Roche Ltd.
1. Company Overview
2. Company Total Revenue (Financials)
3. Market Potential
4. Global Presence
5. Key Performance Indicators
6. SWOT Analysis
7. Product Launch
2. Kyowa Hakko Kirin Co. Ltd.
3. Seattle Genetics Inc.
4. ImmunoGen Inc.
5. Bristol-Myers Squibb Company
6. Pfizer Inc.
7. Amgen Inc
8. Biogen
9. Xencor Inc
10. Other Prominent Players
2. Consultant Recommendation
**The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

RSS
Follow by Email